STOCK TITAN

Pulse Biosciences, Inc. - PLSE STOCK NEWS

Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.

Pulse Biosciences, Inc. (PLSE) is a pioneering clinical-stage electroceutical company focused on the commercial application of its proprietary Nano-Pulse Stimulation (NPS) technology. Headquartered in Hayward, CA, the company's core mission is to leverage this novel technology to improve and extend patient lives, addressing the distinct needs of patients and physicians alike.

Nano-Pulse Stimulation Technology

NPS is a cutting-edge, non-thermal, drug-free energy-based technology that utilizes ultra-short nanosecond electrical pulses to impact cell membranes and intracellular structures. This method promotes unique cellular behaviors and can induce specific immune responses, opening up a myriad of therapeutic possibilities. Unlike conventional treatments, NPS delivers electrical pulses in billionths of a second, providing targeted effects without damaging surrounding tissues.

Applications and Innovations

Pulse Biosciences is actively exploring the potential of its NPS technology across various medical fields. Key areas of investigation include immuno-oncology, where NPS may be used to treat cancer by modulating the immune system's response, and dermatology, for treatments that require precise, non-invasive interventions. The technology's unique biologic effects position it as a promising solution for conditions lacking optimal treatments.

Recent Achievements and Projects

The company has made significant strides in both preclinical and clinical studies, demonstrating the safety and efficacy of NPS technology. Recent projects have focused on refining device capabilities, enhancing treatment protocols, and expanding the scope of applications. Partnerships with leading medical institutions and ongoing collaborations with researchers underscore Pulse Biosciences' commitment to innovation.

Financial Condition

Pulse Biosciences generates substantial revenue primarily from the sale of its systems in North America. The company continues to invest in research and development to further advance its technology and explore new market opportunities.

For those looking to stay updated on the latest developments, performance, and news related to Pulse Biosciences, Inc., StockTitan provides a comprehensive and timely resource.

Rhea-AI Summary

Pulse Biosciences has received FDA Breakthrough Device Designation for its CellFX® nsPFA Cardiac Surgery System, intended for treating atrial fibrillation (AF). The system uses proprietary nanosecond Pulsed Field Ablation™ technology, featuring a surgical clamp that delivers rapid, consistent ablation lesions during cardiac procedures. This approach is significantly faster and potentially safer than current thermal ablation methods, minimizing risk to surrounding tissues.

The designation facilitates expedited development and review processes by the FDA. Pulse Biosciences plans to pursue Premarket Approval (PMA) for commercialization in the U.S. and expects to start its pivotal clinical trial in 2025, with initial human procedures slated for later this year in the Netherlands.

This milestone underscores the technology's promise as a safer and more effective AF treatment, aiming for faster market introduction and improved patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.71%
Tags
-
Rhea-AI Summary

Pulse Biosciences has announced the successful closing of its rights offering, raising $60 million. This offering saw basic and over-subscriptions totaling $83 million, far exceeding the $60 million limit. Over 800 accounts participated, including Executive Chairman Robert Duggan. The rights offering involved the sale of six million units at $10 each, each unit comprising one share of common stock and two warrants. These warrants, exercisable at $11 per share, could potentially bring in an additional $66 million. Half of the warrants are redeemable if the stock trades above $16.50, and the other half if it exceeds $22.00 for twenty days. The funds are set to support product and clinical development, regulatory submissions, and commercial readiness of three leading CellFX nsPFA products. The company now has 61.23 million shares outstanding, excluding the warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the preliminary results of its rights offering, which concluded on June 26, 2024. The offering, oversubscribed by 138%, is expected to generate $60 million in immediate gross proceeds, with potential additional proceeds of up to $66 million from warrant exercises. Each Unit in the $10.00 per Unit offering included one share of common stock and two warrants, with warrants exercisable at $11.00 per share and redeemable under certain conditions. Over 800 accounts participated, including the Company's Executive Chairman, Robert Duggan. The final proceeds and securities distribution will be confirmed upon the closing of the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
Rhea-AI Summary

Pulse Biosciences has commenced a rights offering of up to $60 million in units. Each unit comprises one share of common stock and two warrants to purchase additional shares. The subscription rights, distributed to holders as of May 31, 2024, expire on June 26, 2024. The units are priced at the lesser of $10 per unit or the volume-weighted average price over ten trading days up to the expiration date. The warrants are exercisable immediately and valid for five years. The rights offering includes an over-subscription option, allowing shareholders to buy extra units if available. This offering adheres to the company's SEC registration currently in effect.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
-
Rhea-AI Summary

Pulse Biosciences announced an updated record date for its rights offering to raise up to $60 million. The new record date is May 31, 2024, replacing the original May 16, 2024. This offering allows stockholders to purchase up to 6 million units at a price of either $10 or the volume weighted average price over the ten days preceding the expiration date, June 26, 2024. Each unit includes one share of Common Stock and two warrants. If fully subscribed, the offering will provide gross proceeds of $60 million minus expenses. The Registration Statement is effective, and all details can be found on the SEC’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.4%
Tags
none
-
Rhea-AI Summary

Pulse Biosciences' CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology will be featured in several presentations at the Heart Rhythm Society 2024 Annual Meeting in Boston, MA, from May 16-19. The technology will be highlighted in six presentations and abstracts, including a live case presentation.

The preclinical and initial clinical results for CellFX nsPFA have shown promise, particularly in treating atrial fibrillation. The presentations will cover various aspects of the technology, including preclinical evaluations, first-in-human experiences, and novel catheter designs.

Prominent sessions include a live case demonstrating PVI+ with nsPFA, a presentation on the biophysical insights of novel ablation technologies, and multiple poster sessions on preclinical and clinical assessments of the technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.68%
Tags
none
Rhea-AI Summary

Pulse Biosciences (Nasdaq: PLSE) has appointed Burke T. Barrett as President and CEO, replacing Kevin Danahy, who will become Chief Commercial Officer. Barrett brings over 35 years of experience in the medical device sector, including leadership roles at CardioFocus, Cyberkinetics, and Cyberonics. The leadership changes aim to support the company’s next growth phase, particularly the launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System. Barrett has been granted options to purchase 1.4 million shares at $7.45 per share, subject to vesting over four years and market capitalization milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
management
-
Rhea-AI Summary

Pulse Biosciences, Inc. (PLSE) announced the first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System after FDA clearance. The successful case marks a significant milestone in the company's pilot program, showing promising results in treating soft tissue without damaging noncellular structures. The innovative technology aims to revolutionize patient care with minimal pain and no need for general anesthesia. The company is looking forward to expanding the procedure's usage in 2024, following successful trials in Italy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Pulse Biosciences, Inc. reported business updates and financial results for the first quarter of 2024, highlighting FDA clearance for CellFX nsPFA Percutaneous Electrode, ongoing dialogue with the FDA for CellFX nsPFA Cardiac Clamp, and submission of a feasibility study for CellFX nsPFA 360° Cardiac Catheter. Additionally, the company announced a planned rights offering of up to $60 million to fund growth plans, with a change in record date. Financially, GAAP costs and expenses increased driven by non-cash stock-based compensation, resulting in a net loss of ($10.1) million for Q1 2024. Cash and cash equivalents totaled $34.9 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.21%
Tags
Rhea-AI Summary

Pulse Biosciences, Inc. (PLSE) announced a rights offering for up to $60 million, with a record date set for May 16, 2024. The offering allows common stockholders to purchase Units at $10 or the market price. Each Unit includes one share of common stock and two warrants. The offering includes an over-subscription right. The Registration Statement with the SEC has been filed but is not yet effective.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.92%
Tags
none

FAQ

What is Pulse Biosciences, Inc.?

Pulse Biosciences, Inc. is a clinical-stage electroceutical company focused on commercializing its proprietary Nano-Pulse Stimulation technology.

What is Nano-Pulse Stimulation (NPS) technology?

NPS is a non-thermal, drug-free energy-based technology that uses nanosecond electrical pulses to affect cell membranes and intracellular structures.

What are the primary applications of NPS technology?

NPS technology is being investigated for use in immuno-oncology and dermatology, among other medical fields.

Where is Pulse Biosciences, Inc. headquartered?

The company's headquarters are located in Hayward, CA.

How does NPS technology differ from traditional treatments?

NPS delivers ultra-short electrical pulses that target cells without damaging surrounding tissues, unlike conventional treatments.

What recent achievements has Pulse Biosciences made?

The company has demonstrated the safety and efficacy of NPS in preclinical and clinical studies and is refining its technology.

What are the financial sources for Pulse Biosciences?

The company generates substantial revenue from the sale of its systems, primarily in North America.

How does Pulse Biosciences contribute to medical innovation?

Pulse Biosciences collaborates with leading medical institutions and researchers to advance its NPS technology and explore new applications.

What is the mission of Pulse Biosciences?

The mission is to design, produce, and commercialize Nano-Pulse technology to improve and extend patients' lives.

How can I get the latest updates on Pulse Biosciences?

You can stay informed about the latest developments by following updates on platforms like StockTitan.

Pulse Biosciences, Inc.

Nasdaq:PLSE

PLSE Rankings

PLSE Stock Data

977.20M
61.23M
70.4%
8.74%
4.33%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
HAYWARD